Search

Your search keyword '"Virus latency"' showing total 279 results

Search Constraints

Start Over You searched for: Descriptor "Virus latency" Remove constraint Descriptor: "Virus latency" Publication Type Electronic Resources Remove constraint Publication Type: Electronic Resources
279 results on '"Virus latency"'

Search Results

1. Gene expression and chromatin conformation of microglia in virally suppressed people with HIV

2. CRISPR-Cas9 screen of E3 ubiquitin ligases identifies TRAF2 and UHRF1 as regulators of HIV latency in primary human T cells

Catalog

Books, media, physical & digital resources

3. Characterisation and functional analysis of the murine gammaherpesvirus-68-encoded microRNAs

4. Secreted factors induced by PKC modulators do not indirectly cause HIV latency reversal.

5. The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy.

6. Latency reversal plus natural killer cells diminish HIV reservoir in vivo.

7. KSHV Topologically Associating Domains in Latent and Reactivated Viral Chromatin.

8. KSHV episome tethering sites on host chromosomes and regulation of latency-lytic switch by CHD4.

9. Willingness of Older Canadians with HIV to Participate in HIV Cure Research Near and After the End of Life: A Mixed-Method Study.

10. Novel assays to investigate the mechanisms of latent infection with HIV-2.

11. Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses.

12. Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy.

13. Integrated proteomics and transcriptomics analyses identify novel cell surface markers of HIV latency.

14. G-Quadruplex DNA and Other Non-Canonical B-Form DNA Motifs Influence Productive and Latent HIV-1 Integration and Reactivation Potential.

15. Novel role of UHRF1 in the epigenetic repression of the latent HIV-1.

16. HIV-1 latency is established preferentially in minimally activated and non-dividing cells during productive infection of primary CD4 T cells.

17. Role of the cellular factor CTCF in the regulation of bovine leukemia virus latency and three-dimensional chromatin organization

18. HIV-1 INFECTION MODULATES CD4+ T CELL GENE EXPRESSION TO INDUCE A QUIESCENT PHENOTYPE

19. Tissue-specific differences in HIV DNA levels and mechanisms that govern HIV transcription in blood, gut, genital tract and liver in ART-treated women.

20. Latent cytomegalovirus infection enhances anti-myeloperoxidase autoimmunity and glomerulonephritis in mice.

21. White matter of perinatally HIV infected older youths shows low frequency fluctuations that may reflect glial cycling.

22. Assessing the Suitability of Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size.

23. HIV-1 Genomes Are Enriched in Memory CD4+ T-Cells with Short Half-Lives.

24. Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency.

25. CRISPR Interference Efficiently Silences Latent and Lytic Viral Genes in Kaposi's Sarcoma-Associated Herpesvirus-Infected Cells.

26. CpG Methylation Profiles of HIV-1 Pro-Viral DNA in Individuals on ART.

27. Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study.

28. Micro RNA Targets in HIV Latency: Insights into Novel Layers of Latency Control.

29. Assessing the Suitability of Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size.

30. Distinct viral reservoirs in individuals with spontaneous control of HIV-1.

31. Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir.

32. Replicate Aptima Assay for Quantifying Residual Plasma Viremia in Individuals on Antiretroviral Therapy.

33. A molecular mechanism for probabilistic bet hedging and its role in viral latency.

34. FOXO1 promotes HIV latency by suppressing ER stress in T cells.

35. Human splice factors contribute to latent HIV infection in primary cell models and blood CD4+ T cells from ART-treated individuals.

36. Intact HIV reservoir estimated by the intact proviral DNA assay correlates with levels of total and integrated DNA in the blood during suppressive antiretroviral therapy.

37. Recommendations for measuring HIV reservoir size in cure-directed clinical trials.

38. The HIV-1 latent reservoir is largely sensitive to circulating T cells.

39. Mining for humoral correlates of HIV control and latent reservoir size.

40. Identification of unrecognized host factors promoting HIV-1 latency.

41. Engineering CAR T Cells to Target the HIV Reservoir.

42. Inconsistent reversal of HIV-1 latency ex vivo by antigens of HIV-1, CMV, and other infectious agents.

43. CXCR4-Using HIV Strains Predominate in Naive and Central Memory CD4+ T Cells in People Living with HIV on Antiretroviral Therapy: Implications for How Latency Is Established and Maintained.

44. The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies.

45. Impact of Biological Sex on Immune Activation and Frequency of the Latent HIV Reservoir During Suppressive Antiretroviral Therapy.

46. Single-cell transcriptional landscapes reveal HIV-1-driven aberrant host gene transcription as a potential therapeutic target.

47. Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window.

48. HSF1 inhibition attenuates HIV-1 latency reversal mediated by several candidate LRAs In Vitro and Ex Vivo.

49. Upregulation of Multiple CD8+ T Cell Exhaustion Pathways Is Associated with Recurrent Ocular Herpes Simplex Virus Type 1 Infection.

50. Mechanistic differences underlying HIV latency in the gut and blood contribute to differential responses to latency-reversing agents.